pomalidomide + ketoconazole

**pomalidomide + ketoconazole** represents the simultaneous use of **pomalidomide** (a small molecule immunomodulatory agent, derivative of thalidomide, used primarily for relapsed/refractory multiple myeloma) and **ketoconazole** (a small molecule antifungal agent, and potent inhibitor of cytochrome P450 3A4 and P-glycoprotein)[2][4]. Pomalidomide exerts immunomodulatory, anti-angiogenic, and direct tumoricidal effects primarily via modulation of cereblon and subsequent ubiquitination/degradation of transcription factors, resulting in downregulation of pro-inflammatory cytokines and inhibition of cell proliferation. Ketoconazole inhibits fungal ergosterol synthesis and also inhibits CYP3A4 and P-glycoprotein, altering the pharmacokinetics of drugs metabolized through these pathways.

Other names

pomalidomide